Skip to content

Search

Trans Tasman action to fast track rheumatic fever vaccine

Prime Ministers of Australia and New Zealand have agreed to provide $3M to help fast-track the development of a vaccine against rheumatic fever.

Infectious Disease & Vaccination Public Seminar

Hear the facts about vaccination and infectious disease from some of Australia's leading experts: Professor Jonathan Carapetis, Dr Peter Richmond

State Immunisation Strategy Released

The State Government has launched a new strategy for improving immunisation rates among WA children, to prevent outbreaks of diseases like measles & meningitis

WANTED: 'Flu Busters

Hundreds of healthy volunteers are needed in Perth to test the effectiveness of a current 'flu vaccine.

New vaccine may provide broader protection against cervical cancer

Just under 150 Perth women have contributed to major international research at the Telethon Institute for Child Health Research.

Perth researchers to trial bird flu vaccine

Perth researchers have begun a trial to test the effectiveness of a new vaccine to protect against the potentially deadly bird flu.

New study examines vacccine to prevent cervical cancer

The Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).

Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024

In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.

Socio-economic inequality underpins inequity in influenza vaccination uptake between public and private secondary schools: an Australian population-based study

Socio-economic inequality and vaccination inequity have long been critical issues. However, no studies have explored the gap in influenza vaccination uptake between public and private schools. Importantly, the extent to which socio-economic inequality translates into vaccination uptake inequity has not been quantified.

Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response

SARS-CoV-2 nucleocapsid (N) protein antibodies can be used to identify the serological response to natural infection in those who have previously received a COVID-19 spike-based vaccine. Anti-N antibody responses can also be induced by inactivated whole SARS-CoV-2 virus vaccines, such as CoronaVac. We aimed to characterise antibody responses to the N protein following COVID-19 and following vaccination with CoronaVac.